A share price of BridgeBio Pharma Inc [BBIO] is currently trading at $2980000.0, up 5525654%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The BBIO shares have gain 5.25% over the last week, with a monthly amount glided 23.79%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
BridgeBio Pharma Inc [NASDAQ: BBIO] stock has seen the most recent analyst activity on June 17, 2025, when Wolfe Research initiated its Outperform rating and assigned the stock a price target of $49. Previously, Redburn Atlantic started tracking the stock with Buy rating on March 31, 2025, and set its price target to $50. On October 16, 2024, Scotiabank initiated with a Sector Outperform rating. Oppenheimer started tracking the stock assigning a Perform rating. Piper Sandler initiated its recommendation with a Overweight and recommended $46 as its price target on September 04, 2024. In a note dated January 31, 2024, BMO Capital Markets initiated an Market Perform rating and provided a target price of $37 on this stock.
BridgeBio Pharma Inc experienced fluctuations in its stock price throughout the past year between $21.62 and $41.71. Currently, Wall Street analysts expect the stock to reach $72 within the next 12 months. BridgeBio Pharma Inc [NASDAQ: BBIO] shares were valued at $2980000.0 at the most recent close of the market. An investor can expect a potential drop of -100.0% based on the average BBIO price forecast.
Analyzing the BBIO fundamentals
Trailing Twelve Months sales for BridgeBio Pharma Inc [NASDAQ:BBIO] were 127.42M which represents -44.76% decline. Gross Profit Margin for this corporation currently stands at 0.97% with Operating Profit Margin at -5.48%, Pretax Profit Margin comes in at -5.29%, and Net Profit Margin reading is -5.24%. To continue investigating profitability, this company’s Return on Assets is posted at -0.76, Equity is 0.49 and Total Capital is -0.96. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for BridgeBio Pharma Inc [NASDAQ:BBIO] is 4.57. Also, the Quick Ratio is 4.54, while the Cash Ratio stands at 3.55. Considering the valuation of this stock, the price to sales ratio is 62.19.
Transactions by insiders
Recent insider trading involved Valantine Hannah, Director, that happened on Jun 10 ’25 when 4292.0 shares were sold. Director, HANNAH A VALANTINE completed a deal on Jun 10 ’25 to buy 4292.0 shares. Meanwhile, Chief Executive Officer Kumar Neil sold 75000.0 shares on May 20 ’25.
